By Fineline Cube 
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced the termination of its development collaboration with compatriot firm PharmaBlock (SHE: 300725) regarding the innovative targets and compounds of a 3C protease inhibitor against COVID-19. This decision follows significant changes in the objective environment and market prospects.
Collaboration Background
The partnership, originally established in August 2022, involved the development of a 3C protease inhibitor targeting COVID-19. Aidea Pharma had already made payments to PharmaBlock, including RMB 5 million (USD 681,593) upon project initiation and RMB 885,540 (USD 120,616) for partial raw material costs.
Strategic Realignment
Aidea Pharma views this termination as an opportunity to realign its resources and focus on its advantageous HIV drugs and human-derived protein products. This strategic shift aims to optimize the company’s R&D efforts and market positioning.-Fineline Info & Tech